Desai JV, Lionakis MS
The lysates were incubated with anti-eNOS antibody at 4 C for 1 h
Preclinical safety data In mouse studies, 5-amino-1mq was well-tolerated even at doses several times higher than those producing metabolic effects
But perhaps for some of those peptides that actually need to make it to your gut and stay there as opposed to be systemically absorbed and delivered through your body, its okay that they are there. For musculoskeletal indications (tendons, ligaments, joints), the route is subcutaneous injection near the site of injury
Longer than that, and you should evaluate whether the peptide is still viable
Altered B12 handling and reduced clearance in kidney disease, and both cellular release and reduced clearance in liver disease, can raise B12, so supportive renal or hepatic findings make those causes plausible